Bangladesh Everest Pharmaceuticals' sotoracib is the first generation targeted drug
Sotoraxib (AMG510) is a third-generation tyrosine kinase inhibitor, a drug used to treat adult non-small cell lung cancer, which has been It is used in patients who have received at least one other systemic therapy. It is also used to treat other types of cancer. Sotoracib blocks a protein produced by the mutated KRAS gene (KRAS p.G12C), which may help prevent cancer cells from growing or may also kill them. This is a targeted therapy, also called Lumakras.

At present, Mengjiala Everest Pharmaceuticals has produced this drug and has launched it in Bangladesh. It has government approval. If patients choose to use this drug, they can purchase it through domestic formal channels. The quality of the drug and other aspects are guaranteed.
Before taking sotoracib, tell your doctor and pharmacist if a patient is allergic tosotoracib, any other medicine, or any ingredient insotoracib tablets. Tellthe doctor about other prescription and over-the-counter drugs, vitamins, nutritional supplements, and herbal products that the patient is taking or plans to take. The doctor may need to change the dosage of the medication or carefully monitor for side effects. The following over-the-counter or herbal products may interact with sotolacil: Cimetidine(TagametHB), esomeprazole(Nexium), famotidine
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)